Status:
COMPLETED
Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess long-term outcomes in subjects previously treated with daclatasvir-based therapy for chronic Hepatitis-C (CHC)
Eligibility Criteria
Inclusion
- Males or females 18 years of age or older at initiation of prior DCV-based therapy
- Previously treated with DCV (manufactured by BMS)-based therapy in combination with other HCV direct acting antivirals (DAAs) for at least 8 weeks
- Must enroll in this study within 12 months of end of treatment of DCV-based therapy or within 6 months of protocol availability at the clinical site for subjects treated in the AI447036 or AI447114 studies
Exclusion
- \- N/A
Key Trial Info
Start Date :
April 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2019
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT03366610
Start Date
April 28 2017
End Date
April 30 2019
Last Update
June 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Beijing, Beijing Municipality, China